https://doi.org/10.55788/d77c39ac
A substantial proportion of young women with newly diagnosed breast cancer are interested in future fertility [1]. More than 12% of these young patients carry a germline pathogenic variant in the BRCA1 or BRCA2 genes [2]. Reproductive counselling of pathogenic BRCA carriers is complex, considering the psychological fear of transmitting the genetic variant to their offspring, the possible negative impact of deficient BRCA function on fertility potential, and the indication to undergo risk-reducing bilateral salpingo-oophorectomy at a young age. In addition, while several studies have demonstrated the safety of conceiving following breast cancer diagnosis and treatment, the evidence in pathogenic BRCA carriers is limited [3].
An international, multicentre, hospital-based, retrospective cohort study including young women with history of breast cancer and a pathogenic BRCA variant (NCT03673306) aimed to provide more solid evidence in the field. The study enrolled 4,732 patients, aged 40 years or younger, who were diagnosed with BRCA1- or BRCA2-mutated, stage I–III, invasive breast cancer. The primary endpoints were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary endpoints were breast cancer-specific survival, overall survival, pregnancy, and foetal and obstetric outcomes. Dr Matteo Lambertini (University of Genova, Italy) presented the results [4].
After a median follow-up of 7.8 years, 659 of the participating women had at least 1 pregnancy, and 4,073 had no pregnancy. Cumulative incidence of pregnancy at 10 years was 22% (95% CI 21–24), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR 2.2–5.3 years). In patients with HR-positive disease, cumulative incidence of pregnancy at 10 years was lower (18% vs 26%) and median time to pregnancy was longer (4.3 vs 3.2 years), compared with patients with HR-negative disease. Rates of pregnancy and foetal and obstetric complications were in line with the expectations in a population of women with similar age and no history of breast cancer.
Of note, no significant difference in disease-free survival was observed between women with or without a pregnancy after breast cancer (adjusted HR 0.99; 95% CI 0.81–1.20). The occurrence of pregnancy was associated with a lower rate of breast cancer-specific survival events (adjusted HR 0.60; 95% CI 0.40–0.88; P=0.009).
Dr Lambertini concluded that “this study showed that more than 1 in 5 young women who are pathogenic BRCA carriers became pregnant after a diagnosis of early breast cancer and that disease-free survival was comparable with those who did not become pregnant. Therefore, conceiving after proper treatment and follow-up for breast cancer should not be contraindicated in these women.”
- Ruddy KJ, et al. J Clin Oncol. 2014;32:1151-1156.
- Copson ER, et al. Lancet Oncol. 2018;19:169-180.
- Lambertini M, et al. J Clin Oncol. 2021;39:3293-3305.
- Lambertini M, et al. Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study. Abstract GS02-13, SABCS 2023, 5-9 December, San Antonio, TX, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Interview: Medicare’s first drug price negotiations: concerning? Next Article
Fast menstrual resumption after interruption of endocrine therapy »
« Interview: Medicare’s first drug price negotiations: concerning? Next Article
Fast menstrual resumption after interruption of endocrine therapy »
Table of Contents: SABCS 2023
Featured articles
Olaparib maintenance has favourable safety profile in TNBC
Exercise programme improves quality of life for patients with metastatic breast cancer
Living With & After Breast Cancer
Exercise programme improves quality of life for patients with metastatic breast cancer
Fast menstrual resumption after interruption of endocrine therapy
Pregnancy is not contraindicated in pathogenic BRCA carriers
Early Breast Cancer
Highest benefit of neoadjuvant nivolumab in breast tumours with high PD-L1 expression and/or low ER expression
(More) axillary surgery does not influence long-term recurrence
Neoadjuvant chemotherapy may help patients skip regional nodal irradiation
No radiotherapy after breast-conserving surgery is safe in selected younger patients
HER2-Positive Breast Cancer
Tucatinib improves PFS in metastatic, HER2-positive breast cancer
OS benefit of adjuvant T-DM1 in early breast cancer with residual disease after neoadjuvant therapy
Atezolizumab improves pCR in HER2-positive early breast cancer
HR-Positive/HER2-Negative Breast Cancer
Adjuvant ribociclib improves IDFS in early breast cancer
Addition of inavolisib to palbociclib and fulvestrant reduces risk of progression
Endocrine therapy response provides information on need of adjuvant chemotherapy
monarchE: No predictive biomarkers revealed with molecular profiling
No predictive biomarkers found in PALLAS
Triple-Negative Breast Cancer
Bilateral mastectomy and breast-conserving surgery have equal impact on breast cancer-specific mortality in pathogenic BRCA1 carriers
Olaparib maintenance has favourable safety profile in TNBC
High pCR with neoadjuvant nivolumab/chemotherapy in stage I–II TNBC
Related Articles
January 31, 2022
One in 7 breast cancers detected during screening are overdiagnosed
September 17, 2024
Trastuzumab deruxtecan also effective in patients with brain metastases
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com